The Inevitable Outcome: Diabetes Safety Model Expands To Weight Loss…And Beyond?

The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience – and what it might mean about regulatory expectations for other chronic drug classes in the future.

Cardiologist William Hiatt, MD (University of Colorado School of Medicine) has a problem with the Food and Drug Administration’s proposal to require cardiovascular outcomes studies for all weight loss drugs, even in the absence of a clear signal of CV risk.

“If you want to impose this requirement on a drug with no signals, I think you ought to impose it on all drugs designed for symptomatic indications,” Hiatt declared near the end of the Endocrinologic and Metabolic Drugs Advisory

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo